Phytoecdysteroids as modulators of the Toxoplasma gondii growth rate in human and mouse cells

Parasites and Vectors

Volumn 8, Issue 1, 2015, Pages

  Dzitko, Katarzyna ^a   Grzybowski, Marcin Mikołaj ^a   Pawełczyk, Jakub ^b   Dziadek, Bozena ^a   Gatkowska, Justyna ^a   Stączek, Paweł ^a   Długońska, Henryka ^a  

^a UNIVERSITY OF LODZ   (Poland)

^b INSTITUTE OF MEDICAL BIOLOGY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ECDYSTEROID; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; PHYTOECDYSTEROID; UNCLASSIFIED DRUG; CYTOKINE; ECDYSONE; ECDYSTERONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BABESIA GIBSONI; CELL ISOLATION; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; GROWTH RATE; GROWTH REGULATION; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IN VITRO STUDY; INFECTION SENSITIVITY; INTRACELLULAR KILLING; MAJOR CLINICAL STUDY; MALE; MOUSE; MTT ASSAY; NONHUMAN; PARASITE CULTIVATION; PARASITE DEVELOPMENT; PARASITE VIRULENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SPLEEN CELL; STEROID ANALYSIS; TOXOPLASMA GONDII; TOXOPLASMOSIS; ADULT; AGED; ANIMAL; BAGG ALBINO MOUSE; BRAIN; C57BL MOUSE; CELL SURVIVAL; CYTOLOGY; DOSE RESPONSE; DRUG EFFECTS; GENETICS; GROWTH, DEVELOPMENT AND AGING; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; PARASITOLOGY; SPLEEN; TOXOPLASMA; YOUNG ADULT;

ANIMALIA; BABESIA GIBSONI; MAMMALIA; MURINAE; MUS; STRONGYLOIDES; TOXOPLASMA; TOXOPLASMA GONDII;

ADULT; AGED; ANIMALS; BRAIN; CELL SURVIVAL; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; ECDYSONE; ECDYSTERONE; FEMALE; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MIDDLE AGED; SPLEEN; TOXOPLASMA; TOXOPLASMOSIS; YOUNG ADULT;

EID: 84939148651     PISSN: None     EISSN: 17563305     Source Type: Journal    
DOI: 10.1186/s13071-015-1019-7     Document Type: Article

References (59)

1. Tenter AM, Heckeroth AR, Weiss LM. Toxoplasma gondii: from animals to humans. Int J Parasitol. 2000;30:1217-58.
2. Alvarado-Esquivel C, Pacheco-Vega SJ, Hernández-Tinoco J, Sánchez-Anguiano LF, Berumen-Segovia LO, Rodríguez-Acevedo FJ, et al. Seroprevalence of Toxoplasma gondii infection and associated risk factors in Huicholes in Mexico. Parasit Vectors. 2014;7:301-8.
3. Dzitko K, Malicki S, Komorowski J. Effect of hyperprolactinaemia on Toxoplasma gondii prevalence in humans. Parasitol Res. 2008;102:723-9.
4. Dubremetz JF, Ferguson DJP. The role played by electron microscopy in advancing our understanding of Toxoplasma gondii and other apicomplexans. Int J Parasitol. 2009;39:883-93.
5. Torrey EF, Yolken RH. Toxoplasma gondii and schizophrenia. Emerg Infect Dis. 2003;9:1375-80.
6. Miman O, Kusbeci OY, Aktepe OC, Certinkaya Z. The probable relation between Toxoplasma gondii and Parkinson's disease. Neurosci Lett. 2010;475:129-31.
7. Stommel EW, Seguin R, Thadani VM, Schwartzman JD, Gilbert K, Ryan KA, et al. Cryptogenic epilepsy: an infectious etiology? Epilepsia. 2001;42:436-8.
8. Weiss LM, Dubey JP. Toxoplasmosis: A history of clinical observation. Int J Parasitol. 2009;39:895-901.
9. de Azevedo KML, Setubal S, Lopes VGS, Camacho LA, Oliveira SA. Congenital toxoplasmosis transmitted by human immunodeficiency-virus infected women. Braz J Infect Dis. 2010;14:186-9.
10. Petersen E, Schmidt DR. Sulfadiazine and pyrimethamine in the postnatal treatment of congenital toxoplasmosis: what are the options? Expert Rev Anti Infect Ther. 2003;1:175-82.
11. Dibbern Jr DA, Montanaro A. Allergies to sulfonamide antibiotics and sulfur-containing drugs. Ann Allergy Asthma Immunol. 2008;100:91-100.
12. Dziadek B, Gatkowska J, Grzybowski M, Dziadek J, Dzitko K, Dlugonska H. Toxoplasma gondii: the vaccine potential of three trivalent antigen-cocktails composed of recombinant ROP2, ROP4, GRA4 and SAG1 proteins against chronic toxoplasmosis in BALB/c mice. Exp Parasitol. 2012;131:133-8.
13. Chuang S-C, Ko J-C, Chen C-P, Du J-T, Yang C-D. Induction of long-lasting protective immunity against Toxoplasma gondii in BALB/c mice by recombinant surface antigen 1 protein encapsulated in poly (lactide-co-glycolide) microparticles. Parasit Vectors. 2013;6:34.
14. Cong H, Zhang M, Xin Q, Wang Z, Li Y, Zhao Q, et al. Compound DNA vaccine encoding SAG1/ SAG3 with A2/B subunit of cholera toxin as a genetic adjuvant protects BALB/c mice against Toxoplasma gondii. Parasit Vectors. 2013;6:63.
15. Martins-Duarte ES, Urbina JA, de Souza W, Vommaro RC. Antiproliferative activities of two novel quinuclidine inhibitors against Toxoplasma gondii tachyzoites in vitro. J Antimicrob Chemother. 2006;58:59-65.
16. Dzitko K, Paneth A, Plech T, Pawełczyk J, Stączek P, Stefańska J, et al. 1,4-disubstituted thiosemicarbazide derivatives are potent inhibitors of Toxoplasma gondii proliferation. Molecules. 2014;19:9926-43.
17. Dzitko K, Paneth A, Plech T, Pawełczyk J, Weglinska L, Paneth P. Triazole-based compounds as the candidate to develop a novel medicines to treat toxoplasmosis. Antimicrob Agents Chemother. 2014;58:7583-5.
18. Asgari Q, Keshavarz H, Rezaeian M, Motazedian MH, Shojaee S, Mohebali M, et al. Direct effect of two naphthalene-sulfonyl-indole compounds on Toxoplasma gondii tachyzoite. J Parasitol Res. 2013;2013:1-8.
19. Bilia AR, de Malgalhaes PM, Bergonzi MC, Vincieri FF. Simultaneous analysis of artemisinin and flavonoids of several extracts of Artemisia annua L. obtained from a commercial sample and a selected cultivar. Phytomedicine. 2006;13:487-93.
20. Jones-Brando L, D'Angelo L, Posner GH, Yolken R. In vitro inhibition of Toxoplasma gondii by four new derivatives of artemisinin. Antimicrob Agents Chemother. 2006;50:4206-8.
21. Dzitko K, Gatkowska J, Plocinski P, Dziadek B, Długońska H. The effect of prolactin (PRL) on the growth of Toxoplasma gondii tachyzoites in vitro. Parasitol Res. 2010;107:199-204.
22. Gueye PEO, Diallo M, Deme AB, Badiane AS, Dior DM, Ahouidi A, et al. Tea Artemisia annua inhibits Plasmodium falciparum isolates collected in Pikine, Senegal. Afr J Biochem Res. 2013;7:107-12.
23. Choi KM, Gang J, Yun J. Anti-Toxoplasma gondii RH strain activity of herbal extracts used in traditional medicine. Int J Antimicrob Agents. 2008;32:360-2.
24. Subeki MH, Matsuura H, Takahashi K, Yamasaki M, Yamato O, Maede Y, et al. Antibabesial activity of protoberberine alkaloids and 20- hydroxyecdysone from Arcangelisia flava against Babesia gibsoni in culture. J Vet Med Sci. 2005;67:223-7.
25. Burg JL, Grover CM, Pouletty P, Boothroyd JC. Direct and sensitive detection of a pathogenic protozoan, Toxoplasma gondii, by polymerase chain reaction. J Clin Microbiol. 1989;27:1787-92.
26. Wahab T, Edvinsson B, Palm D, Lindh J. Comparison of the AF146527 and B1 repeated elements, two real-time PCR targets used for detection of Toxoplasma gondii. J Clin Microbiol. 2010;48:591-2.
27. Grigg ME, Sundar N. Sexual recombination punctuated by outbreaks and clonal expansions predicts Toxoplasma gondii population genetics. Int J Parasitol. 2009;39:925-33.
28. Dubey JP, Lindsay DS, Speer CA. Structures of Toxoplasma gondii tachyzoites, bradyzoites, and sporozoites and biology and development of tissue cysts. Clin Microbiol. 1998;11:267-99.
29. Lijnen P, Saavedra A, Petrov V. In vitro proliferative response of human peripheral blood mononuclear cells to concanavalin A. Clin Chim Acta. 1997;264:91-101.
30. Tomar A, Bansal MP, Ram GC. Maintenance of concanavalin A stimulated T lymphocytes from peripheral blood of goats. Small Rum Res. 1995;18:89-94.
31. Pfefferkorn ER, Pfefferkorn LC. Specific labeling of intracellular Toxoplasma gondii with uracil. J Protozool. 1977;24:449-53.
32. Meneceur P, Bouldouyre MA, Aubert D, Villena I, Menotti J, Sauvage V, et al. In vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine, and atovaquone. Antimicrob Agents Chemother. 2008;52:1269-77.
33. Doliwa C, Escotte-Binet S, Aubert D, Velard F, Schmid A, Geers R, et al. Induction of sulfadiazine resistance in vitro in Toxoplasma gondii. Exp Parasitol. 2013;133:131-6.
34. De Oliveira TC, Silva DA, Rostkowska C, Béla SR, Ferro EA, Magalhães PM, et al. Toxoplasma gondii: Effects of Artemisia annua L. on susceptibility to infection in experimental models in vitro and in vivo. Exp Parasitol. 2009;122:233-41.
35. van der Ven AJ, Schoondermark-van de Ven EM, Camps W, Melchers WJ, Koopmans PP, van der Meer JW, et al. Anti-toxoplasma effect of pyrimethamine, trimethoprim and sulphonamides alone and in combination: implications for therapy. J Antimicrob Chemother. 1996;38:75-80.
36. Jin C, Jung SY, Kim SY, Song HO, Park H. Simple and efficient model systems of screening anti-Toxoplasma drugs in vitro. Expert Opin Drug Discovery. 2012;7:195-205.
37. Cortez MR, Provençano A, Silva CE, Mello CB, Zimmermann LT, Schaub GA, et al. Trypanosoma cruzi: effects of azadirachtin and ecdysone on the dynamic development in Rhodnius prolixus larvae. Exp Parasitol. 2012;131:363-71.
38. Barker GC, Mercer JG, Rees HH, Howells RE. The effect of ecdysteroids on the microfilarial production of Brugia pahangi and the control of meiotic reinitiation in the oocytes of Dirofilaria immitis. Parasitol Res. 1991;77:65-71.
39. Townson S, Tagboto SK. In vitro cultivation and development of Onchocerca volvulus and Onchocerca lienalis microfilariae. Am J Trop Med Hyg. 1996;54:32-7.
40. Satoh M, Kiyuna S, Shiroma Y, Toma H, Kokaze A, Sato Y. Predictive markers for development of strongyloidiasis in patients infected with both Strongyloides stercoralis and HTLV-1. Clin Exp Immunol. 2003;133:391-6.
41. Siddiqui AA, Stanley CS, Skelly PJ, Berk SL. A cDNA encoding a nuclear hormone receptor of the steroid/thyroid hormone-receptor superfamily from the human parasitic nematode Strongyloides stercoralis. Parasitol Res. 2000;86:24-9.
42. Nisbet AJ, Cottee P, Gasser RB. Molecular biology of reproduction and development in parasitic nematodes: progress and opportunities. Int J Parasitol. 2004;34:125-38.
43. Báthori M, Tóth N, Hunyadi A, Márki A, Zador E. Phytoecdysteroids and anabolic-androgenic steroids structure and effects on humans. Curr Med Chem. 2008;15:75-91.
44. Sláma K, Koudela K, Tenora J, Mathova A. Insect hormones in vertebrates: anabolic effects of 20-hydroxyecdysone in Japanese quails. Experientia. 1996;52:702-6.
45. Kratky F, Opletal L, Hejhalek J, Kucharova S. Effect of 20-hydroxyecdysone on the protein synthesis of pigs. Zivocisna Vyroba. 1997;42:445-51.
46. Trenin DS, Volodin VV. 20-hydroxyecdysone as a human lymphocyte and neutrophil modulator: In vitro evaluation. Arch Insect Biochem Physiol. 1999;41:156-61.
47. Hung TJ, Chen WM, Liu SF, Liao TN, Lee TC, Chuang LY, et al. 20-Hydroxyecdysone attenuates TGF-β1-induced renal cellular fibrosis in proximal tubule cells. J Diabetes Complications. 2012;26:463-9.
48. Harmatha J, Vokác K, Kmonícková E, Zídek Z. Lack of interference of common phytoecdysteroids with production of nitric oxide by immune-activated mammalian macrophages. Steroids. 2008;73:466-71.
49. Taniguchi SF, Bersani-Amado CA, Sudo LS, Assef SMC, Oga S. Effect of Pfaffia iresinoides on the experimental inflammatory process in rats. Phytother Res. 1997;11:568-71.
50. Peschel W, Kump A, Prieto JM. Effects of 20-hydroxyecdysone, Leuzea carthamoides extracts, dexamethasone and their combinations on the NF-κB activation in HeLa cells. J Pharm Pharmacol. 2011;63:1483-95.
51. Kim JM, Oh YK, Kim YJ, Cho SJ, Ahn MH, Cho YJ. Nuclear factor-kappa B plays a major role in the regulation of chemokine expression of HeLa cells in response to Toxoplasma gondii infection. Parasitol Res. 2001;87:758-63.
52. Du J, An R, Chen L, Shen Y, Chen Y, Cheng L, et al. Toxoplasma gondii virulence factor ROP18 inhibits the host NF-κB pathway by promoting p65 degradation. J Biol Chem. 2014;289:12578-92.
53. Shapira S, Speirs K, Gerstein A, Caamano J, Hunter CA. Suppression of NF-kappaB activation by infection with Toxoplasma gondii. J Infect Dis. 2002;185 Suppl 1:S66-72.
54. Rosowski EE, Lu D, Julien L, Rodda L, Gaiser RA, Jensen KD, et al. Strain-specific activation of the NF-kappaB pathway by GRA15, a novel Toxoplasma gondii dense granule protein. J Exp Med. 2011;208:195-212.
55. Molestina RE, Payne TM, Coppens I, Sinai AP. Activation of NF-kappaB by Toxoplasma gondii correlates with increased expression of antiapoptotic genes and localization of phosphorylated IkappaB to the parasitophorous vacuole membrane. J Cell Sci. 2003;116:4359-71.
56. Payne TM, Molestina RE, Sinai AP. Inhibition of caspase activation and a requirement for NF-kappaB function in the Toxoplasma gondii-mediated blockade of host apoptosis. J Cell Sci. 2003;116:4345-58.
57. Molestina RE, Sinai AP. Host and parasite-derived IKK activities direct distinct temporal phases of NF-kappaB activation and target gene expression following Toxoplasma gondii infection. J Cell Sci. 2005;118:5785-96.
58. Butcher BA, Kim L, Johnson PF, Denkers EY. Toxoplasma gondii tachyzoites inhibit proinflammatory cytokine induction in infected macrophages by preventing nuclear translocation of the transcription factor NF-kappa B. J Immunol. 2001;167:2193-201.
59. Caamaño J, Alexander J, Craig L, Bravo R, Hunter CA. The NF-kappa B family member RelB is required for innate and adaptive immunity to Toxoplasma gondii. J Immunol. 1999;163:4453-61.